A verified CJC-1295 DAC test report provides essential third-party documentation of chemical identity, purity, and bioburden levels for laboratory evaluation. Evaluating Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) chromatograms and Electrospray Ionization Mass Spectrometry (ESI-MS) spectra ensures that researchers utilize high-purity growth hormone-releasing hormone (GHRH) analogs capable of yielding reproducible preclinical data in growth hormone and IGF-1 axis studies.
A verified CJC-1295 DAC test report provides essential third-party documentation of chemical identity, purity, and bioburden levels for laboratory evaluation. Evaluating Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) chromatograms and Electrospray Ionization Mass Spectrometry (ESI-MS) spectra ensures that researchers utilize high-purity growth hormone-releasing hormone (GHRH) analogs capable of yielding reproducible preclinical data in growth hormone and IGF-1 axis studies.
In modern peptide synthesis, relying solely on manufacturer declarations is insufficient for rigorous quantitative research. A comprehensive cjc-1295 dac test report serves as a objective audit of a lot's chemical fidelity, establishing both purity percentages and molecular identity through independent laboratory verification.
When inspecting a Certificate of Analysis (COA) for CJC-1295 with Drug Affinity Complex (DAC), principal investigators must look beyond simple overall purity figures. A standard analytical suite generated by an ISO 17025-accredited testing facility typically measures three critical parameters: chromatographic purity via RP-HPLC, molecular weight verification using Mass Spectrometry (MS), and bacterial endotoxin quantification via Limulus Amebocyte Lysate (LAL) assays. Together, these metrics verify that the research compound is free from structural truncations, deletion sequences, and biological contaminants.
For laboratory teams conducting long-term studies on the pituitary-somatotropic axis, accessing raw test reports is essential for data integrity. Unintended synthesis impurities—such as unblocked side-chain species or racemized amino acid residues—can alter receptor binding kinetics at the GHRH receptor (GHRHR), confounding baseline measurements in both *in vitro* cell culture assays and *in vivo* rodent models. Accessing transparent, lot-traceable documentation through our dedicated research hub allows procurement officers to validate every batch prior to study initiation.
CJC-1295 with DAC is a synthetic 30-amino acid tetrasubstituted peptide derivative of natural growth hormone-releasing hormone (GHRH 1-29). The sequence incorporates specific amino acid substitutions—D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27—designed to enhance enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV) cleavage.
The defining structural modification of CJC-1295 DAC is the addition of a Lysine residue at the C-terminus conjugated to a maleimido-propionic acid (MPA) linker. This Drug Affinity Complex (DAC) reactive group enables bioconjugation to nucleophilic thiol groups on endogenous serum albumin following administration in animal models. Preclinical studies indicate that covalent binding to circulating albumin dramatically extends the compound's elimination half-life from minutes to approximately 6 to 8 days, preserving biological activity across extended observation windows.
Through sustained activation of pituitary somatotroph GHRH receptors, CJC-1295 DAC stimulates cyclic adenosine monophosphate (cAMP) signal transduction pathways, triggering the synthesis and secretion of endogenous growth hormone (GH). In rodent models, this prolonged activation produces dose-dependent elevations in downstream insulin-like growth factor 1 (IGF-1) concentrations without ablating the natural pulsatile pattern of GH secretion. Consequently, researchers frequently select this compound for investigations into cell proliferation, nitrogen retention, and metabolic pathways linked to tissue repair.
When evaluating a cjc-1295 dac test report, researchers should systematically review distinct quantitative parameters to confirm that the material meets stringent analytical specifications for laboratory use:
1. **Purity Percentage (RP-HPLC):** High-Performance Liquid Chromatography must demonstrate a primary peak representing no less than 98.0% (ideally ≥99.0%) of the total integrated peak area. Impurities representing deletion peptides or incomplete coupling products should remain below established detection thresholds. 2. **Molecular Weight Confirmation (MS):** Mass Spectrometry must show a dominant m/z signal matching the theoretical monoisotopic or average molecular weight of CJC-1295 DAC (C152H252N44O42, MW ~3647.28 Da). 3. **Endotoxin Content:** Endotoxin levels, measured in Endotoxin Units per milligram (EU/mg), must fall well below standard preclinical safety thresholds (<0.01 EU/mg) to prevent non-specific inflammatory responses in cellular or tissue assays. 4. **Counter-Ion Content and Residual Solvents:** Assessment of residual trifluoroacetic acid (TFA) content ensures that the lyophilized peptide cake will not alter culture media pH or introduce unexpected cytotoxicity during assays.
Cross-referencing these four criteria provides an empirical safeguard against product batch variations, ensuring that experimental results reflect the true biological activity of the primary peptide rather than background contaminants or degraded fragments.
A rigorous analytical test report presents the raw chromatographic trace alongside tabular integration data. In RP-HPLC analysis, a single, sharp, symmetrical peak with minimal tailing confirms high chemical purity. Symmetrical peaks indicate that the stationary phase effectively separated the main target peptide from hydrophobic or hydrophilic synthetic side-products, such as oxidized methionine variants or acetylated sequences.
Mass spectrometry analysis further validates the identity of the compound. For CJC-1295 DAC, Electrospray Ionization Mass Spectrometry (ESI-MS) typically displays multicharged ion species—such as [M+3H]3+, [M+4H]4+, and [M+5H]5+—which, upon mathematical deconvoluting, yield the correct calculated molecular mass of 3647.28 Da. Discrepancies between theoretical and observed mass peaks strongly point to sequence errors, missing amino acid residues, or failed conjugation of the maleimide moiety.
Understanding how to interpret these data sets is critical for research integrity. Laboratories utilizing our peptide purity HPLC analysis guide can cross-examine raw spectrum graphs against standard benchmark criteria, verifying that every lot delivered to the facility aligns with peer-reviewed laboratory standards.
Bacterial endotoxins—lipopolysaccharides (LPS) derived from Gram-negative bacterial cell walls—represent a pervasive source of experimental error in cell culture and preclinical laboratory models. Even minor endotoxin contamination can stimulate Toll-like receptor 4 (TLR4) signaling, triggering cytokine cascades that distort cellular proliferation, protein expression, and receptor sensitivity assays.
Standard laboratory protocols require that research peptides undergo rigorous quantitative endotoxin testing prior to release. Utilizing kinetic chromogenic or turbidimetric LAL assays, testing labs measure the presence of pyrogenic substances down to sub-picogram sensitivity. For high-grade research materials, endotoxin content is controlled to less than 0.01 EU/mg.
By enforcing strict bioburden controls during manufacturing and packaging in GMP-compliant, sterile cleanrooms, researchers can confidently introduce reconstituted compounds into sensitive *in vitro* primary cell cultures or rodent models without inducing confounding immune or inflammatory responses. Detailed protocols on bioburden mitigation are covered in our guide on endotoxin testing standards.
To select the appropriate growth hormone secretagogue for specific experimental designs, researchers must evaluate structural and pharmacokinetic differences across the GHRH analog class. The presence or absence of the Drug Affinity Complex fundamentally dictates dosing frequency and half-life parameters in animal models.
While CJC-1295 DAC exhibits an extended serum half-life due to its albumin-binding capacity, CJC-1295 No DAC (also referred to as Mod GRF 1-29) lacks the maleimido-propionic acid linker. Consequently, CJC-1295 No DAC exhibits a much shorter half-life (~30 minutes in rodent models), making it suitable for studies designed to simulate acute, short-duration GH pulses rather than continuous serum elevations.
Other classical secretagogues offer distinct receptor affinity profiles. For instance, Sermorelin represents the native 29-amino acid N-terminal sequence of GHRH, displaying rapid clearance and requiring frequent administration in experimental models. Conversely, Tesamorelin incorporates a trans-3-hexenoic acid group attached to the N-terminal Tyr residue, optimized specifically for studies evaluating lipolysis and deep visceral adipose tissue reduction. Reviewing the full range of compounds in our all peptides catalog helps laboratory personnel select the exact kinetic profile required for their study parameters.
Maintaining peptide stability following delivery requires adherence to standardized storage and handling procedures. Lyophilized CJC-1295 DAC should be stored upon receipt in a temperature-controlled freezer at -20°C or -80°C, protected from light and ambient moisture. Under these conditions, the un-reconstituted peptide cake maintains chemical stability for extended durations.
Reconstitution must be executed inside a laminar flow hood using sterile laboratory technique. The preferred solvent for most analytical assays is sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride injection solution. Solvent should be introduced slowly down the interior glass wall of the vial to avoid rapid agitation, which can induce physical shearing or mechanical aggregation of delicate peptide chains.
Once dissolved, reconstituted aliquots should be used immediately or frozen in single-use working volumes to eliminate repeated freeze-thaw cycles. Repeated thermal cycling causes hydrophobic aggregation and degradation, leading to lost biological activity and reduced chromatographic purity over time. For step-by-step laboratory handling guidelines, consult our reconstitution and storage guide.
Reliable research outcomes depend on consistent product quality across multiple supply cycles. PX1 Research addresses this need by enforcing rigorous quality control protocols across every lot of synthesized peptides. All compounds are manufactured in domestic, GMP-compliant facilities adhering to strict quality management systems.
Every batch of CJC-1295 DAC is assigned a unique lot number that directly corresponds to an independent third-party cjc-1295 dac test report. These reports are generated by ISO 17025-accredited analytical testing laboratories, guaranteeing impartial verification of RP-HPLC purity, ESI-MS identity, and LAL endotoxin levels prior to catalog placement.
To prevent thermal degradation during transit, orders are dispatched with same-day processing (Monday through Friday) from optimized distribution hubs in California and Arizona. Procurement officers establishing recurring delivery schedules or bulk experimental protocols can explore dedicated commercial supply options through our wholesale lab account portal.
cjc-1295 dac test report
A CJC-1295 DAC test report is an independent, third-party Certificate of Analysis (COA) detailing the chemical purity (via RP-HPLC), molecular identity (via ESI-MS), and endotoxin levels (via LAL assay) of a specific peptide lot. It confirms that the material meets laboratory standards (≥98% purity, <0.01 EU/mg endotoxin) prior to use in preclinical research.
What is the theoretical molecular weight of CJC-1295 DAC on a mass spectrometry report?
The theoretical average molecular weight of CJC-1295 DAC (chemical formula C152H252N44O42) is approximately 3647.28 Da. A valid mass spectrometry test report should show deconvoluted mass peaks matching this calculated molecular weight within standard experimental error margins.
How do I interpret the RP-HPLC chromatogram in a CJC-1295 DAC test report?
The RP-HPLC chromatogram shows signal intensity plotted against retention time. A high-purity compound exhibits a sharp, single major peak. Purity is calculated by integrating the area under the primary peak as a percentage of the total area of all detected peaks across the run.
Why is endotoxin testing critical for CJC-1295 DAC research compounds?
Endotoxins (lipopolysaccharides) provoke non-specific inflammatory responses in cellular and animal models via TLR4 activation. Verifying an endotoxin level below 0.01 EU/mg ensures that cell culture viability and biomarker responses reflect peptide activity rather than immune activation.
What is the difference between CJC-1295 DAC and CJC-1295 No DAC in test reports?
CJC-1295 DAC contains a C-terminal Lysine modified with maleimido-propionic acid (MPA), adding significant mass (MW ~3647.28 Da vs. ~3367.9 Da for No DAC). Mass spectrometry test reports easily differentiate the two compounds by their distinct molecular weights.
What purity threshold is required for quantitative preclinical CJC-1295 DAC studies?
Preclinical assays typically require a minimum chromatographic purity of 98.0%, with many advanced cell culture and receptor binding protocols specifying ≥99.0% purity to eliminate confounding effects from truncated side-products.
How should lyophilized CJC-1295 DAC be stored upon receipt in the laboratory?
Lyophilized CJC-1295 DAC should be stored at -20°C or -80°C in a desiccated container protected from light. Under proper freezing conditions, un-reconstituted vials retain baseline purity and stability over long-term storage periods.
What solvents are recommended for reconstituting CJC-1295 DAC for lab use?
Reconstitution is typically performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride. Solvents should be added gently down the vial wall to prevent agitation, foaming, and protein shearing.
Does PX1 Research supply lot-specific test reports with every CJC-1295 DAC shipment?
Yes. Every batch of CJC-1295 DAC offered by PX1 Research features lot-traceable COAs generated by independent ISO 17025 accredited laboratories, verifying purity, molecular identity, and bioburden parameters.
What is the shipping protocol for CJC-1295 DAC orders from PX1 Research?
Orders are processed and shipped same-day Monday through Friday from fulfillment centers in California and Arizona, utilizing temperature-controlled, protective packaging to preserve compound stability during transit.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.